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Abstract
Background: Major depressive disorder (MDD) is highly prevalent in Japan and frequently accompanied by
insomnia that may persist even with MDD remission. Hypnotics are used for the pharmacological treatment of
insomnia, but their influence on MDD recurrence or residual insomnia following MDD remission is unclear. This
retrospective, longitudinal, cohort study utilized a large Japanese health insurance claims database to investigate
patterns of hypnotic prescriptions among patients with MDD, and the influence of hypnotic prescription pattern on
MDD recurrence.
Methods: Eligible patients (20–56 years) were those registered in the Japan Medical Data Center database between
1 January 2005 and 31 December 2018, and prescribed antidepressant and hypnotic therapy after being diagnosed
with MDD. Patients who had ceased antidepressant therapy for > 180 days were followed for 1 year to evaluate
depression recurrence, as assessed using Kaplan-Meier estimates. Logistic regression modelling was used to analyze
the effect of hypnotic prescription pattern on MDD recurrence.
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Results: Of the 179,174 patients diagnosed with MDD who initiated antidepressant treatment between 1 January
2006 and 30 June 2017, complete prescription information was available for 2946 eligible patients who had been
prescribed hypnotics. More patients were prescribed hypnotic monotherapy (70.8%) than combination therapy
(29.2%). The most prescribed therapies were benzodiazepine monotherapy (26.2%), non-benzodiazepine
monotherapy (28.9%), and combination therapy with two drugs (21.1%). Among patients prescribed multiple
hypnotics, concomitant prescriptions for anxiolytics, antipsychotics, mood stabilizers and sedative antidepressants
were more common. The 1-year recurrence rate for MDD was approximately 20%, irrespective of hypnotic mono-
versus combination therapy or class of hypnotic therapy. Being a spouse (odds ratio [OR], 1.44; 95% confidence
interval [CI], 1.03–2.02) or other family member (OR, 1.46, 95% CI, 0.99–2.16) of the insured individual, or being
prescribed a sedative antidepressant (OR, 1.50, 95% CI, 1.24–1.82) conferred higher odds of MDD recurrence within
1 year of completing antidepressant therapy.
Conclusions: Benzodiazepines are the most prescribed hypnotic among Japanese patients with MDD, though
combination hypnotic therapy is routinely prescribed. Hypnotic prescription pattern does not appear to influence
real-world MDD recurrence, though hypnotics should be appropriately prescribed given class differences in efficacy
and safety.
Keywords: Major depressive disorder, Depression, Residual symptom, Insomnia, Recurrence, Japanese patients,
Prescription pattern
Background
Major depressive disorder (MDD) is highly prevalent in
Japan, with a 12-month prevalence of 2.2–2.7% and life-
time prevalence of 6.1% [1, 2]. However, because only
around 20% of Japanese patients with a mental disorder
seek medical care [3], the prevalence of MDD may be
higher than currently estimated. MDD is a leading cause
of disability both globally and in Japan [4], and is associ-
ated with reduced quality of life, lower work productiv-
ity, and a substantial economic burden [5–7].
Treatment for MDD generally involves antidepressant
therapy to achieve clinical remission and prevent relapse
[8]. However, an estimated 20% of patients with MDD
experience a recurrence within 6 months of recovery [8].
Relapse rates are particularly high among patients who
discontinue treatment early [8], which may be particu-
larly important among Japanese patients, in whom me-
dian treatment duration tends to be shorter than
guideline recommendations [9].
Around one-quarter of patients with MDD have re-
sidual symptoms following remission [8], such as de-
pressed mood, anxiety, and insomnia [10]. Importantly,
residual symptoms are associated with MDD relapse and
recurrence [10, 11]. Insomnia, in particular, is a common
residual symptom experienced by more than 50% of pa-
tients, which, in addition to increasing the risk of MDD
relapse, is associated with reduced quality of life [10, 12].
Hypnotic therapies, including benzodiazepine and
non-benzodiazepine drugs, sedative–hypnotic drugs
(such as sedating antidepressants), melatonin, and
orexin-receptor antagonists, are used in the pharmaco-
logical treatment of insomnia [13, 14]. Hypnotic therap-
ies are commonly co-prescribed with antidepressants to
manage depression-associated insomnia [13, 15]. While
hypnotic therapies can improve sleep for patients with
depression-associated residual insomnia [16, 17], they
have also been associated with an increased risk of de-
veloping a psychiatric disorder [18]. High doses of hyp-
notics have also been linked to antidepressant
refractoriness and worse depression outcomes [19].
Therefore, this retrospective cohort study aimed to in-
vestigate real-world patterns of hypnotic prescribing
among Japanese patients with MDD, and the influence
of hypnotic prescription pattern on MDD recurrence, by
interrogating the Japan Medical Data Center (JMDC)
Inc. insurance claims database, which comprises accu-
mulated health insurance receipt data (inpatient, out-
patient, dispensing) from multiple health insurance
associations in Japan for > 7 million individuals. The
database also contains patients’ medical examination
data including diagnosis and treatment information, en-
abling longitudinal tracking of patients across different
healthcare providers.
Methods
Data sources, study population and cohort selection
We retrospectively analyzed anonymized health insur-
ance claims data collated in the JMDC Inc. database
(system version: Netezza N2002 010 7.1.0.4.P2; Tokyo,
Japan), which comprises accumulated receipts (inpatient,
outpatient and dispensing) and medical examination
data received from multiple health insurance associa-
tions relating to 7,175,048 people in Japan, between 1
January 2005 and 31 December 2018. Eligible patients
received a diagnosis of primary or recurrent MDD
(World Health Organization’s International Statistical
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Classification of Diseases and Related Health Problems
[10th ed.; ICD-10] codes F32 or F33, respectively) and
were prescribed antidepressant therapy, defined as a se-
lective serotonin reuptake inhibitor (SSRI), serotonin–
noradrenaline reuptake inhibitor (SNRI), noradrenergic
or specific serotonergic antidepressant, or tricyclic anti-
depressant (World Health Organization’s Anatomical
Therapeutic Chemical [ATC] codes N06A4, N06A5,
N06A9 and N06A9, respectively) and a hypnotic (non-
barbiturate, monotherapy; ATC code N05B1) between 1
January 2006 and 30 June 2017 (the study enrollment
period; Fig. 1).
The index date was the date on which all antidepres-
sant treatment was expected to be completed following
dispensing of the final antidepressant prescription. Eli-
gible patients must have had ≥1 period of ≥180 days
without antidepressant treatment after the index date
(the treatment completion period). Patients were also re-
quired to be aged ≥20 years at the time of initiating anti-
depressant therapy and < 65 years within the entire
observable period from starting antidepressant therapy
of up to 540 days from the index date. Patients must
have had continuous health insurance enrollment for
≥12months prior to the earliest diagnosis of depression
during the study enrollment period.
Patients were excluded from the study if they had been
diagnosed with MDD and not prescribed an antidepres-
sant, or prescribed antidepressants or hypnotics without
a diagnosis of MDD during the baseline period (365 days
prior to first being diagnosed with MDD and prescribed
an antidepressant).
Variables
Outcomes assessed in this exploratory study were the
pattern of hypnotic prescription for depression-
associated insomnia, and the impact of hypnotic pre-
scription patterns on time to MDD relapse, defined as
the reissue of a prescription for antidepressant therapy
after a > 180-day period without antidepressant therapy,
in combination with a hypnotic for residual insomnia.
Predictor variables included patients’ demographic
characteristics, insurance enrolment category (insured,
spouse, or other dependent family member), prior or
concomitant diagnosis of other psychiatric disorders
(anxiety disorder, autism, schizophrenia, attention deficit
hyperactivity disorder, bipolar disorder [ICD-10 codes:
F20-F31, F40-F45, F48, F84.0, F90.0]), prior or concomi-
tant use of other medications, (ATC codes: A01A-,
A02B1, A02B2, A07E2, C01A1, C01B-, C02A1, C02A2,
C02B2, C02C-, C02D-, C03A2, C03A3, C05A1, C06X-,
C07A-, D05X-, D06A-, D07A-, D07B1, D07B4, D11A-,
G01A1, G01A2, G03B-, G03C-, G03D-, G03E-, G03F-,
G03G-, G03J-, G03X-, G04A2, H01A-, H02A1, H02A2,
H02B-, H03A-, J01A-, J01C1, J01C2, J01E-, J01X9,
J03A-, J04A1, J05B3, J05D1, J08B-, L01C1, L01D-,
L01X9, L03B1, L03B2, L03B3, L04X-, M01A1, M02A-,
M03B-, N01A2, N02B-, N03A-, N04A-, N05A9, N05BA,
N05BA01-N05BA03, N05BA05, N05BA06, N05BA08,
N05BA09, N05BA11, N05BA12, N05BA17-N05BA19,
N05BA21-N05BA23, N05BB01, N05BE, N05B3, N07A-,
N07E-, N07X-, R01A1, R02A-, R03D1, R03F1, R03L3,
R05A-, R06A-, S01A-, S01B-, S01E1, S01E2, S01R-,
S02C-, S03B-, S03C-), prescription for sedative
Fig. 1 Study design
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antidepressant medications (mirtazapine, trazodone
hydrochloride, mianserin hydrochloride), antidepressant
dosage at the end of treatment (less than or greater than
the recommended maximum dose), the daily
imipramine-equivalent dose of antidepressant (< 75 mg/
day, ≥75 and < 150 mg/day, or ≥ 150 mg/day) [20]. Prior
disorders were those diagnosed < 12 months before the
diagnosis and treatment of depression. Concomitant
medications were those prescribed ≤6 months before the
follow-up period.
Patients’ hypnotic prescription pattern was categorized
as benzodiazepine monotherapy, non-benzodiazepine
monotherapy, melatonin receptor agonists, orexin recep-
tor antagonists, two agents combined, three agents com-
bined, or ≥ 4 drugs.
Statistical analysis
Patient demographics, clinical characteristics and study
variables were summarized using descriptive statistics
(mean, standard deviation [SD], median, interquartile
range [IQR]). If the date of prescription was missing
from the receipt, the last day of the month in which the
doctor’s office visit occurred was used. If the dose of
medication was missing, the data point was removed
from the analysis.
The impact of hypnotic prescribing patterns on MDD
recurrence during the follow-up period was assessed
using Kaplan-Meier estimates.
Logistic regression modelling was used to analyze the
effect of hypnotic prescription pattern on MDD relapse,
with time to MDD relapse as the dependent variable,
hypnotic prescription pattern as an explanatory variable,
and demographic/clinical characteristics as independent
variables. Adjusted odds ratios (OR) and 95% confidence
intervals (CI) were calculated using a Cox proportional
hazards model. A stepwise method was used to select
variables to be included in the final model, using an in-
clusion significance level of < 0.1 and exclusion signifi-
cance level of ≥0.05. A final logistic regression model
was developed using age and gender (mandatory vari-
ables) and all significant predictors of MDD relapse, with
the 1-year recurrence rate as the dependent variable and
residual insomnia as an explanatory variable.
All statistical analyses were conducted using SAS ver-
sion 9.4 (TS1M4; SAS Institute Japan Ltd., Tokyo,
Japan).
Results
Of the 179,174 patients diagnosed with MDD who initi-
ated antidepressant treatment between 1 January 2006
and 30 June 2017, 36,192 patients fulfilled the eligibility
criteria for this study (Fig. 2). Of those, ≥1-year follow-
up data was available for 30,381 patients, of whom 4166
had been prescribed hypnotics for residual insomnia
during the follow-up period. Among those prescribed
hypnotics for residual insomnia, complete prescription
information was available for 2946 patients (the total an-
alyzed population).
Patient demographics and treatment pattern
Patients in the total analyzed population (n = 2946) were
mostly male (62.8%) and aged ≥40 years (58.8%), with a
mean (SD) age of 41.6 (10.2) years (Table 1). Approxi-
mately three-quarters of patients were insured em-
ployees (74.2%). All other patients were the spouse
(19.2%) or another family member (6.6%) of the insured
individual. While anxiety disorder (16.6%) was the most
prevalent psychiatric condition prior to MDD diagnosis,
bipolar disorder (85.4%), anxiety disorder (40.7%) and
schizophrenia (15.8%) were the most commonly comor-
bid psychiatric disorders at the time of diagnosis with
MDD. Steroidal and hormonal drugs (48.8%) and anxio-
lytics (18.8%) were the most commonly prescribed medi-
cations prior to MDD diagnosis. At the time of diagnosis
with MDD, 37.9% of patients were prescribed steroidal
and hormonal drugs and concomitant anxiolytics, anti-
psychotics, and mood stabilizers were prescribed to 48.4,
20.6 and 7.3% of patients, respectively. Mirtazapine
(20.4%) was the most frequently prescribed sedative anti-
depressant, followed by trazodone hydrochloride
(12.2%), and mianserin hydrochloride (3.2%). At the end
of treatment, almost all patients (93%) were receiving
less than the maximum recommended dose of
antidepressant.
The vast majority of patients (70.8%) were prescribed
hypnotic monotherapy rather than combination therapy
comprising ≥2 drugs (29.2%). Most prescriptions were
for benzodiazepine monotherapy (36.2%) and non-
benzodiazepine monotherapy (28.9%), followed by com-
bination therapy with two drugs (21.1%). Patient demo-
graphics and clinical characteristics among hypnotic
prescription subgroups were generally comparable to the
total analyzed population regarding age, male sex, insur-
ance type, prior and concomitant psychiatric disorders
and medications, sedative antidepressant prescriptions,
and antidepressant dosage at the end of treatment. Simi-
larly, patient demographics and clinical characteristics
were generally comparable between patients prescribed
monotherapy versus combination therapy, except that a
greater proportion of patients prescribed hypnotic
monotherapy were aged ≥40 years (61.2% vs 52.9%), and
more patients prescribed combination hypnotic therapy
had comorbid schizophrenia (24.1% vs 12.4%). Further-
more, concomitant prescriptions for antipsychotics and
mood stabilizers were more common among patients
prescribed combination hypnotic therapy (31.4 and
13.5%) versus monotherapy (16.1 and 4.7%). Specifically,
the rate of concomitant antipsychotic prescriptions was
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28.6, 35.5 and 46.5% among patients prescribed two-,
three- or ≥ 4-drug combination hypnotic therapy, re-
spectively, versus 20.6% overall. Similarly, while 7.3% of
patients were prescribed mood stabilizers overall, com-
bination hypnotic therapies were associated with mood
stabilizer prescription rates of 11.7, 15.7 and 23.9%, re-
spectively. Concomitant prescriptions for anxiolytics also
tended to be higher among patients prescribed three-
drug (57.8%) or ≥ 4-drug (62.0%) combination hypnotic
therapy. Prescriptions for sedative antidepressants also
tended to be higher among patients prescribed two-
(24.0%), three- (25.9%) or ≤ 4-drug (28.2%) combination
hypnotic therapies; a similar pattern was observed with
trazodone hydrochloride and mianserin hydrochloride
prescriptions.
Overall, mean antidepressant dosage was notably
higher among patients prescribed combination therapy
than monotherapy (83.1 vs 70.7 mg/day). Specifically,
mean antidepressant dosage was higher among patients
prescribed two- (82.5 imipramine-equivalent mg/day),
three- (87.7 imipramine-equivalent mg/day), or ≥ 4-drug
(77.4 imipramine-equivalent mg/day) combination hyp-
notic therapy compared with the total analyzed popula-
tion (74.3 imipramine-equivalent mg/day).
Effect of hypnotic prescription pattern on MDD
recurrence
There were no differences in MDD recurrence rates be-
tween patients prescribed monotherapy versus combin-
ation therapy for residual insomnia, or according to class
of hypnotic prescribed (Fig. 3). Specifically, 1-year recur-
rence rates were 20% (n = 213) with benzodiazepine,
17.2% (n = 146) with non-benzodiazepine, 18.4% (n = 14)
with melatonin receptor agonist and 18.1% (n = 17) with
orexin receptor antagonist therapy. Recurrence rates
were 18.7% (n = 390) with hypnotic monotherapy versus
23.3% (n = 200) with combination treatment. Given the
intersecting natures of the Kaplan-Meier curves (Fig. 3),
we did not conduct log-rank and Wilcoxon tests to com-
pare recurrence rates between groups.
Factors associated with MDD recurrence
Among patients prescribed hypnotic therapy for
depression-associated residual insomnia, the odds of
MDD recurrence within 1 year of completing antidepres-
sant therapy were higher among those who were a
spouse (OR, 1.44; 95% CI, 1.03–2.02) or other family
member (OR, 1.46; 95% CI, 0.99–2.16) of the insured
individual, and those who were prescribed a sedative
antidepressant (OR, 1.50, 95% CI, 1.24–1.82; Table 2),
but lower among females (OR, 0.67; 95% CI, 0.50–0.88).
In contrast, prescription pattern did not influence the
odds of MDD recurrence.
Discussion
This retrospective study utilized a large health insurance
claims database to explore hypnotic prescription pat-
terns and depression recurrence among Japanese pa-
tients with MDD. The findings illustrate that among
patients with MDD prescribed hypnotic therapy, most
were prescribed monotherapy after ceasing antidepres-
sant therapy, predominantly benzodiazepines, while
about one-third of patients were prescribed combination
hypnotic therapy comprising ≥2 drugs. Importantly, con-
comitant prescriptions for anxiolytics, antipsychotics,
mood stabilizers and sedative antidepressants were more
common among patients prescribed multiple hypnotic
therapies.
In patients prescribed combination hypnotic therapy,
antidepressant dosages were substantially higher com-
pared with patients prescribed monotherapy, which may
reflect greater severity of depression or antidepressant-
resistant depression in patients prescribed combination
therapy. While severe depression is considered a risk
factor for MDD recurrence [8, 21], there was no differ-
ence in recurrence rates according to hypnotic prescrip-
tion in this study. Accordingly, hypnotic combination
therapy may have prevented MDD recurrence in patients
with severe depression.
While a previous study reported a significantly higher
risk of depressive disorders over 6 years with long-term
sedative–hypnotic prescriptions, including benzodiaze-
pines in patients with insomnia [18], the current findings
suggest depression recurrence among Japanese patients
is unaffected by hypnotic prescription over a shorter, 1-
year period. Likewise, no differences in MDD recurrence
rates was observed between patients prescribed hypnotic
monotherapy versus combination therapy, or between
classes of hypnotic therapy. However, it must be noted
that sedatives and hypnotics are considered to be a
short-term solution for managing insomnia, and this
study has investigated their use in this context.
These findings confirm the relatively high rates of psy-
chotropic polypharmacy in Japan [9, 22, 23]. Although
Japanese treatment guidelines for MDD recommend
antidepressant monotherapy, in reality around three-
(See figure on previous page.)
Fig. 2 Flow diagram of study participants. aA diagnosis of depression accompanied by prescription of antidepressants; bHas continuous health
insurance enrollment; cExcluding the month immediately preceding the earliest treatment for diagnosis only; dHad no antidepressant treatment
for ≥180 continuous days; eUp to 360 days following the last day of the first untreated period of 180 continuous days. JMDC; Japan Medical
Data Center
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(16.6)
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(0.6)
2 (0.3) 0 (0) 0 2 (0.2)
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(1.4)
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(1.1)
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Yamato et al. BMC Psychiatry           (2021) 21:40 Page 8 of 12
quarters of patients with MDD are prescribed multiple
therapies [9]. Benzodiazepines formed the backbone of
antidepressant therapy and combination therapy in this
study, in concordance with benzodiazepine monotherapy
being the preferred initial treatment for MDD among
Japanese clinicians [24], and a combination of first- and/
or second-generation antidepressants and benzodiaze-
pines were the predominant polypharmacy [9].
That hypnotic therapy with two drugs was more com-
mon than ≥3-drug regimens is perhaps not surprising,
and may reflect the reduced payments from public in-
surance payers to medical institutions if ≥3 hypnotics
are simultaneously prescribed [22]. Likewise, our obser-
vation that almost all patients were prescribed less than
the recommended maximum dose of antidepressants is
in keeping with prescribing practices in Japan [22].
Therefore, if depression-associated insomnia can be ef-
fectively managed using fewer medications, without in-
creasing the risk of depression recurrence, then
combination therapy – with its potential for drug–drug
interactions – should be avoided whenever possible. Fur-
thermore, consideration should be given to the hypnotic
prescribed for depression-associated insomnia because
efficacy and safety varies across classes. For example,
benzodiazepines are associated with multiple adverse
events, including cognitive and psychomotor impair-
ment, amnesia, next-day hangover, rebound insomnia
and dependence [13]. In contrast, newer hypnotic ther-
apies including melatonin agonists, improve sleep with-
out producing residual sedation, or memory, cognitive
or psychomotor impairment [13]. In this study, no dif-
ference in MDD recurrence was found by hypnotic drug
type, suggesting that these advantages may be realized
without increasing risk of depression relapse in patients
with residual insomnia. However, a recent meta-analysis
has reported differences in MDD relapse rates according
to class of antidepressant therapy [25].
This study is limited by the JMDC database only pro-
viding data for employees aged 20–64 years and their
spouse or family members, and the majority of study
subjects (62.8%) were male, meaning the results may not
be generalizable to the overall Japanese population. Fur-
thermore, the database does not capture the criteria used
to diagnose patients with MDD and the severity of de-
pression, which could influence diagnostic and prescrib-
ing patterns. Likewise, patients with severe depression
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aAnalysis set for 1-year recurrence rate; bWithin 12 months prior to treatment for depression; cWithin 6 months before start of the follow-up period; dConverted to
values that are equivalent to imipramine using a dose-equivalence scale for antidepressants [20].
ADHD Attention deficit hyperactivity disorder, CI Confidence interval, IQR Interquartile range, SD Standard deviation
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have a higher risk of being unemployed, and would
therefore not be captured in the JMDC database [26],
which could be evidenced by the higher odds of recur-
rence in spouses and other family members versus in-
sured employees observed in this study.
Similarly, a filled prescription claim does not indicate
consumption of, or adherence to, prescription medica-
tion and it was assumed that patients who discontinued
antidepressant treatment were in remission, as opposed
to failing to return to a healthcare provider to refill their
prescription. Likewise, it was inferred that patients were
prescribed hypnotic therapy during follow-up to manage
depression-associated residual insomnia.
Conclusions
The rates of MDD recurrence in patients receiving hyp-
notics for residual insomnia was not affected by hypnotic
monotherapy versus combination therapy, or class of
hypnotic therapy, indicating that choice of ongoing
treatment for insomnia is unlikely to increase the risk of
recurrent MDD once antidepressant therapy ceases for
real-world Japanese patients. Benzodiazepine monother-
apy is the most commonly prescribed hypnotic among
Japanese patients with MDD, though a substantial pro-
portion of patients are prescribed ≥2 hypnotic therapies.
Hypnotics should be appropriately prescribed for
depression-associated insomnia, given differences in effi-
cacy and safety across classes of hypnotics. Newer clas-
ses of hypnotics may be useful for avoiding some of the
drawbacks of benzodiazepine therapy.
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